OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
| 1.361 | |
| 1.38 | |
| - | |
| 1.47 | |
| 1.35 | |
| 1.09-3.07 | |
| 44 869 K | |
| 33 236 K | |
| 0 | |
| 0 | |
| -3.3 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary shareSimultaneous extinguishment of $4.20M of payables by issuing 2,766,667...
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP.S...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
